DEXCOM, INC. DexCom, Inc. Share Price London S.E.
Equities
0A4M
US2521311074
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
After market 18:25:49 | |||
| 126 USD | -2.68% |
|
115 | -8.76% |
| 05-30 | Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target | MT |
| 05-24 | Declaration of Voting Results by DexCom, Inc | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.33B 339B | Sales 2025 * | 5.15B 403B | Capitalization | 47.23B 3,695B |
|---|---|---|---|---|---|
| Net income 2024 * | 732M 57.27B | Net income 2025 * | 910M 71.2B | EV / Sales 2024 * | 11.2 x |
| Net Debt 2024 * | 1.43B 112B | Net Debt 2025 * | 994M 77.79B | EV / Sales 2025 * | 9.36 x |
| P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
53.7
x | Employees | 9,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
More news
| 1 day | -8.76% | ||
| 1 week | -1.47% | ||
| Current month | +7.43% | ||
| 1 month | +0.24% | ||
| 3 months | +3.27% | ||
| 6 months | +8.09% | ||
| Current year | +1.18% |
1 week
116.77
128.52
1 month
116.77132.10
Current year
113.16141.97
1 year
74.71141.97
3 years
67.29164.71
5 years
67.29164.71
10 years
67.29164.71
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 31/10/07 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 31/08/18 |
| Chief Tech/Sci/R&D Officer | 47 | 30/09/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 19/11/09 |
Mark Foletta
BRD | Director/Board Member | 63 | 18/11/14 |
Eric Topol
BRD | Director/Board Member | 69 | 08/07/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 117.3 | -0.65% | 6,684 |
| 30/05/24 | 118.1 | -7.54% | 1,949 |
| 29/05/24 | 127.7 | +0.47% | 1,264 |
| 28/05/24 | 127.1 | -0.63% | 1,929 |
Delayed Quote London S.E., May 13, 2024 at 03:39 pm
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
05/06/2024
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
118.8
USD
Average target price
150.3
USD
Spread / Average Target
+26.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.44% | 178B | |
| -1.05% | 107B | |
| -2.52% | 67.04B | |
| +11.51% | 44.62B | |
| +9.25% | 42.5B | |
| +14.86% | 29.99B | |
| +15.97% | 25.22B | |
| -7.51% | 24.14B | |
| -6.37% | 23.69B |
- Stock Market
- Equities
- DXCM Stock
- 0A4M Stock
